Annexon Reports Positive Q4 and Full-Year 2025 Results, Highlights Key Milestones

Vonaprument Phase 3 Data Expected Q4 2026; Tanruprubart MAA Filed in Europe; ANX1502 Advancing in Autoimmune Trials

Mar. 31, 2026 at 3:38am

Got story updates? Submit your updates here. ›

A minimalist studio still life featuring a collection of polished, geometric objects in muted tones, conceptually representing Annexon's scientific innovation in neuroinflammatory disease research.Annexon's targeted approach to blocking neuroinflammation at its source aims to reshape treatment for debilitating diseases impacting millions.Brisbane Today

Annexon, a biopharmaceutical company advancing targeted immunotherapies for neuroinflammatory diseases, reported its Q4 and full-year 2025 financial results and highlighted key portfolio progress and anticipated milestones. The company's two late-stage programs, vonaprument for geographic atrophy and tanruprubart for Guillain-Barré syndrome, are positioned to potentially improve the lives of millions in large, underserved markets. Annexon also shared updates on the advancement of its first-in-kind oral C1 inhibitor, ANX1502, in autoimmune disease trials.

Why it matters

Annexon's targeted approach to blocking the classical complement pathway at its source aims to provide meaningful functional benefits and alter the course of serious neuroinflammatory diseases. The potential approvals of vonaprument and tanruprubart could address significant unmet needs for patients with vision loss from geographic atrophy and nerve paralysis from Guillain-Barré syndrome, respectively.

The details

Vonaprument, Annexon's lead program targeting C1q to preserve vision in geographic atrophy, is on track to report pivotal Phase 3 ARCHER II data in Q4 2026. The trial is the first to evaluate visual acuity preservation as the primary endpoint. Tanruprubart, designed to protect peripheral nerves in Guillain-Barré syndrome, has an MAA filed in Europe and a U.S./EU FORWARD study underway to support a planned BLA submission in 2026. Annexon's first-in-class oral C1 inhibitor, ANX1502, is advancing in a proof-of-concept trial for autoimmune disease, with data expected in 2026.

  • Annexon reported Q4 and full-year 2025 financial results on March 30, 2026.
  • Vonaprument Phase 3 ARCHER II topline data is expected in Q4 2026.
  • Tanruprubart MAA was filed in Europe, with U.S./EU FORWARD study data expected to support a planned BLA submission in 2026.
  • ANX1502 proof-of-concept data in autoimmune disease is anticipated in 2026.

The players

Annexon, Inc.

A biopharmaceutical company advancing targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide.

Douglas Love

President and chief executive officer of Annexon.

Got photos? Submit your photos here. ›

What they’re saying

“We're energized by this defining period for Annexon. Two decades of C1q and classical complement pathway research have enabled our bold mission of pioneering a new class of targeted immunotherapies that reshape how neuroinflammation is treated.”

— Douglas Love, President and Chief Executive Officer

“Today, our scientific platform has translated into two late stage registrational programs with the potential to improve the lives of millions in large, underserved markets worldwide.”

— Douglas Love, President and Chief Executive Officer

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Annexon's focus on blocking the classical complement pathway at its source with targeted therapies like vonaprument and tanruprubart could provide meaningful functional benefits and alter the course of serious neuroinflammatory diseases, addressing significant unmet needs for patients.